SCOTUS to hear out Teva on Copaxone delay

Share this article:

Teva announced today that the Supreme Court will hear its appeal in a move to delay generic competition for the drugmaker's multiple sclerosis treatment Copaxone. Teva hopes to extend the drug's patent life through September 2015. Its current patent for Copaxone is set to expire in May of this year.

In January FDA approved a new version of Copaxone that allows patients to take the drug three times a week rather than daily. The drugmaker, according to Reuters, says that it believes 45% of regular Copaxone patients will switch to the new form of the drug.  Leerink Partners analyst Jason Gerberry said he expects that 25% of current Copaxone patients will be switched by June, about 33% by year end and 40% in two years, also reported by Reuters.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.